Virtual screening of natural compounds as selective inhibitors of polo-like kinase-1 at C-terminal polo box and N-terminal catalytic domain

References

• Abdelfatah, S., Berg, A., Böckers, M., & Efferth, T. (2019). A selective inhibitor of the polo-box domain of polo-like kinase 1 identified by virtual screening. Journal of Advanced Research, 16, 145–156. https://doi.org/10.1016/j.jare.2018.10.002
   PubMed Web of Science ®Google Scholar
• Abraham, C. S., Muthu, S., Prasana, J. C., Armaković, S., Armaković, S. J., Rizwana B, F., Geoffrey, B., & David R, H. A. (2019). Computational evaluation of the reactivity and pharmaceutical potential of an organic amine: A DFT, molecular dynamics simulations and molecular docking approach. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 222, 117188. https://doi.org/10.1016/j.saa.2019.117188
   PubMed Web of Science ®Google Scholar
• Aguilar, B., Anandakrishnan, R., Ruscio, J. Z., & Onufriev, A. V. (2010). Statistics and physical origins of pK and ionization state changes upon protein-ligand binding. Biophysical Journal, 98(5), 872–880. https://doi.org/10.1016/j.bpj.2009.11.016
   PubMed Web of Science ®Google Scholar
• Ahinko, M., Niinivehmas, S., Jokinen, E., & Pentikäinen, O. T. (2019). Suitability of MMGBSA for the selection of correct ligand binding modes from docking results. Chemical Biology & Drug Design, 93(4), 522–538. https://doi.org/10.1111/cbdd.13446
   PubMed Web of Science ®Google Scholar
• AlAjmi, M. F., Rehman, M. T., Hussain, A., & Rather, G. M. (2018). Pharmacoinformatics approach for the identification of Polo-like kinase-1 inhibitors from natural sources as anti-cancer agents. International Journal of Biological Macromolecules, 116, 173–181. https://doi.org/10.1016/j.ijbiomac.2018.05.023
   PubMed Web of Science ®Google Scholar
• Ando, K., Ozaki, T., Yamamoto, H., Furuya, K., Hosoda, M., Hayashi, S., Fukuzawa, M., & Nakagawara, A. (2004). Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. The Journal of Biological Chemistry, 279(24), 25549–25561. https://doi.org/10.1074/jbc.M314182200
   PubMed Web of Science ®Google Scholar
• Archambault, V., & Normandin, K. (2017). Several inhibitors of the Plk1 polo-box domain turn out to be non-specific protein alkylators. Cell Cycle (Georgetown, Tex.), 16(12), 1220–1224. https://doi.org/10.1080/15384101.2017.1325043
   PubMed Web of Science ®Google Scholar
• Barr, F. A., Silljé, H. H. W., & Nigg, E. A. (2004). Polo-like kinases and the orchestration of cell division. Nature Reviews. Molecular Cell Biology, 5(6), 429–441. https://doi.org/10.1038/nrm1401
   PubMed Web of Science ®Google Scholar
• Bochevarov, A. D., Harder, E., Hughes, T. F., Greenwood, J. R., Braden, D. A., Philipp, D. M., Rinaldo, D., Halls, M. D., Zhang, J., & Friesner, R. A. (2013). Jaguar: A high‐performance quantum chemistry software program with strengths in life and materials sciences. International Journal of Quantum Chemistry, 113(18), 2110–2142. https://doi.org/10.1002/qua.24481
   Web of Science ®Google Scholar
• Chang, C. Y., & Schiano, T. D. (2007). Review article: drug hepatotoxicity. Alimentary Pharmacology & Therapeutics, 25(10), 1135–1151. https://doi.org/10.1111/j.1365-2036.2007.03307.x
   PubMed Web of Science ®Google Scholar
• Chekkara, R., Kandakatla, N., Gorla, V. R., Tenkayala, S. R., & Susithra, E. (2017). Theoretical studies on benzimidazole and imidazo [1, 2-a] pyridine derivatives as Polo-like kinase 1 (Plk1) inhibitors: Pharmacophore modeling, atom-based 3D-QSAR and molecular docking approach. Journal of Saudi Chemical Society, 21, S311–S321. https://doi.org/10.1016/j.jscs.2014.03.007
   Web of Science ®Google Scholar
• Cheng, K., Lowe, E. D., Sinclair, J., Nigg, E. A., & Johnson, L. N. (2003). The crystal structure of the human polo-like kinase-1 polo box domain and its phospho-peptide complex. The EMBO Journal, 22(21), 5757–5768. https://doi.org/10.1093/emboj/cdg558
   PubMed Web of Science ®Google Scholar
• Consonni, V., Ballabio, D., & Todeschini, R. (2010). Evaluation of model predictive ability by external validation techniques. Journal of Chemometrics, 24(3–4), 194–201. https://doi.org/10.1002/cem.1290
   Web of Science ®Google Scholar
• Cruz, J. V., Neto, M. F. A., Silva, L. B., Ramos, R. D. S., Costa, J. D. S., Brasil, D. S. B., Lobato, C. C., da Costa, G. V., Bittencourt, J. A. H. M., da Silva, C. H. T. P., Leite, F. H. A., & Santos, C. B. R. (2018). Identification of novel protein kinase receptor type 2 inhibitors using pharmacophore and structure-based virtual screening. Molecules, 23(2), 453. https://doi.org/10.3390/molecules23020453
   PubMed Web of Science ®Google Scholar
• Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7(1), 1–13. https://doi.org/10.1038/srep42717
   PubMed Web of Science ®Google Scholar
• Dallakyan, S., & Olson, A. J. (2015). Small-molecule library screening by docking with PyRx. Methods In Chemical biology (pp. 243–250). New York, NY: Humana press. https://doi.org/10.1007/978-1-4939-2269-7_19.
   Google Scholar
• de Cárcer, G., Escobar, B., Higuero, A. M., García, L., Ansón, A., Pérez, G., Mollejo, M., Manning, G., Meléndez, B., Abad-Rodríguez, J., & Malumbres, M. (2011). Plk5, a polo box domain-only protein with specific roles in neuron differentiation and glioblastoma suppression. Molecular and Cellular Biology, 31(6), 1225–1239. https://doi.org/10.1128/MCB.00607-10
   PubMed Web of Science ®Google Scholar
• Descombes, P., & Nigg, E. A. (1998). The polo‐like kinase Plx1 is required for M phase exit and destruction of mitotic regulators in Xenopus egg extracts. The EMBO Journal, 17(5), 1328–1335. https://doi.org/10.1093/emboj/17.5.1328.
   PubMed Web of Science ®Google Scholar
• Dixon, S. L., Duan, J., Smith, E., Von Bargen, C. D., Sherman, W., & Repasky, M. P. (2016). AutoQSAR: An automated machine learning tool for best-practice quantitative structure–activity relationship modeling. Future Medicinal Chemistry, 8(15), 1825–1839.
   PubMed Web of Science ®Google Scholar
• Duong‐Ly, K. C., & Peterson, J. R. (2013). The human kinome and kinase inhibition. Current Protocols in Pharmacology, 60(1), 2–9. https://doi.org/10.1002/0471141755.ph0209s60
   Google Scholar
• Eaton, B. E., Gold, L., & Zichi, D. A. (1995). Let’s get specific: The relationship between specificity and affinity. Chemistry & Biology, 2(10), 633–638. https://doi.org/10.1016/1074-5521(95)90023-3
   PubMedGoogle Scholar
• Eckerdt, F., & Strebhardt, K. (2006). Polo-like kinase 1: Target and regulator of anaphase-promoting complex/cyclosome–dependent proteolysis. Cancer Research, 66(14), 6895–6898. https://doi.org/10.1158/0008-5472.CAN-06-0358
   PubMed Web of Science ®Google Scholar
• Egan, W. J., Merz, K. M., & Baldwin, J. J. (2000). Prediction of drug absorption using multivariate statistics. Journal of Medicinal Chemistry, 43(21), 3867–3877. https://doi.org/10.1021/jm000292e
   PubMed Web of Science ®Google Scholar
• Ferguson, F. M., & Gray, N. S. (2018). Kinase inhibitors: The road ahead. Nature Reviews. Drug Discovery, 17(5), 353–377. https://doi.org/10.1038/nrd.2018.21
   PubMed Web of Science ®Google Scholar
• Fry, A. M., O'Regan, L., Sabir, S. R., & Bayliss, R. (2012). Cell cycle regulation by the NEK family of protein kinases. Journal of Cell Science, 125(Pt 19), 4423–4433. https://doi.org/10.1242/jcs.111195
   PubMed Web of Science ®Google Scholar
• Ghose, A. K., Viswanadhan, V. N., & Wendoloski, J. J. (1998). Prediction of hydrophobic (lipophilic) properties of small organic molecules using fragmental methods: An analysis of ALOGP and CLOGP methods. The Journal of Physical Chemistry A, 102(21), 3762–3772. https://doi.org/10.1021/jp980230o
   Web of Science ®Google Scholar
• Ghose, A. K., Viswanadhan, V. N., & Wendoloski, J. J. (1999). A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. Journal of Combinatorial Chemistry, 1(1), 55–68. https://doi.org/10.1021/cc9800071
   PubMedGoogle Scholar
• Gjertsen, B. T., & Schöffski, P. (2015). Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. Leukemia, 29(1), 11–19. https://doi.org/10.1038/leu.2014.222
   PubMed Web of Science ®Google Scholar
• Gutteridge, R. E. A., Ndiaye, M. A., Liu, X., & Ahmad, N. (2016). Plk1 inhibitors in cancer therapy: From laboratory to clinics. Molecular Cancer Therapeutics, 15(7), 1427–1435. https://doi.org/10.1158/1535-7163.MCT-15-0897
   PubMed Web of Science ®Google Scholar
• Halgren, T. A., Murphy, R. B., Friesner, R. A., Beard, H. S., Frye, L. L., Pollard, W. T., & Banks, J. L. (2004). Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. Journal of Medicinal Chemistry, 47(7), 1750–1759.https://doi.org/10.1021/jm030644s
   PubMed Web of Science ®Google Scholar
• Harder, E., Damm, W., Maple, J., Wu, C., Reboul, M., Xiang, J. Y., Wang, L., Lupyan, D., Dahlgren, M. K., Knight, J. L., Kaus, J. W., Cerutti, D. S., Krilov, G., Jorgensen, W. L., Abel, R., & Friesner, R. A. (2016). OPLS3: A force field providing broad coverage of drug-like small molecules and proteins. Journal of Chemical Theory and Computation, 12(1), 281–296. https://doi.org/10.1021/acs.jctc.5b00864
   PubMed Web of Science ®Google Scholar
• Huang, X., Xie, Z., & Liao, C. (2020). Developing polo-like kinase 1 inhibitors. Future Science, 12(10), 869-871. https://doi.org/10.4155/fmc-2020-0055
   Google Scholar
• Huggins, D. J., Hardwick, B. S., Sharma, P., Emery, A., Laraia, L., Zhang, F., Narvaez, A. J., Roberts-Thomson, M., Crooks, A. T., Boyle, R. G., Boyce, R., Walker, D. W., Mateu, N., McKenzie, G. J., Spring, D. R., & Venkitaraman, A. R. (2019). Development of a novel cell-permeable protein-protein interaction inhibitor for the polo-box domain of polo-like kinase 1. ACS Omega, 5(1), 822–831.https://doi.org/10.1021/acsomega.9b03626
   PubMed Web of Science ®Google Scholar
• Iwaloye, O., Elekofehinti, O. O., Momoh, A. I., Babatomiwa, K., & Ariyo, E. O. (2020). In silico molecular studies of natural compounds as possible anti-Alzheimer’s agents: Ligand-based design. Network Modeling Analysis in Health Informatics and Bioinformatics, 9(1), 1–14. https://doi.org/10.1007/s13721-020-00262-7
   Web of Science ®Google Scholar
• Karnik, K. S., Narula, I. S., Sarkate, A. P., & Wakte, P. S. (2020). Auto QSAR‐A fast approach for creation and application of QSAR models through automation. ChemistrySelect, 5(19), 5756–5762. https://doi.org/10.1002/slct.202000744
   Web of Science ®Google Scholar
• Khalid, M., Ullah, M. A., Adeel, M., Khan, M. U., Tahir, M. N., & Braga, A. A. C. (2019). Synthesis, crystal structure analysis, spectral IR, UV–Vis, NMR assessments, electronic and nonlinear optical properties of potent quinoline based derivatives: Interplay of experimental and DFT study. Journal of Saudi Chemical Society, 23(5), 546–560. https://doi.org/10.1016/j.jscs.2018.09.006
   Web of Science ®Google Scholar
• Kothe, M., Kohls, D., Low, S., Coli, R., Cheng, A. C., Jacques, S. L., Johnson, T. L., Lewis, C., Loh, C., Nonomiya, J., Sheils, A. L., Verdries, K. A., Wynn, T. A., Kuhn, C., & Ding, Y.-H. (2007). Structure of the catalytic domain of human polo-like kinase 1. Biochemistry, 46(20), 5960–5971. https://doi.org/10.1021/bi602474j
   PubMed Web of Science ®Google Scholar
• Kothe, M., Kohls, D., Low, S., Coli, R., Rennie, G. R., Feru, F., Kuhn, C., & Ding, Y. (2007). Selectivity-determining residues in Plk1. Chemical Biology & Drug Design, 70(6), 540–546. https://doi.org/10.1111/j.1747-0285.2007.00594.x
   PubMed Web of Science ®Google Scholar
• Kumar, M., Pydi, S. P., Sharma, S., Singh, T. P., & Kaur, P. (2014). Identification of a high affinity selective inhibitor of Polo-like kinase 1 for cancer chemotherapy by computational approach. Journal of Molecular Graphics & Modelling, 51, 104–112. https://doi.org/10.1016/j.jmgm.2014.04.014
   PubMed Web of Science ®Google Scholar
• Lee, W. M. (2003). Drug-induced hepatotoxicity. New England Journal of Medicine, 349(5), 474–485. https://doi.org/10.1056/NEJMra021844
   PubMed Web of Science ®Google Scholar
• Liao, C., Park, J.-E., Bang, J. K., Nicklaus, M. C., & Lee, K. S. (2010). Probing binding modes of small molecule inhibitors to the Polo-box domain of human Polo-like kinase 1. ACS Medicinal Chemistry Letters, 1(3), 110–114. https://doi.org/10.1021/ml100020e
   PubMed Web of Science ®Google Scholar
• LigPrep. (2017). 2: LigPrep. Schrödinger, LLC.
   Google Scholar
• Liu, X., & Erikson, R. L. (2003). Polo-like kinase 1 in the life and death of cancer cells. Cell Cycle (Georgetown, Tex.), 2(5), 424–424.
   PubMed Web of Science ®Google Scholar
• MacCorkle, R. A., & Tan, T.-H. (2005). Mitogen-activated protein kinases in cell-cycle control. Cell Biochemistry and Biophysics, 43(3), 451–461. https://doi.org/10.1385/CBB:43:3:451
   PubMed Web of Science ®Google Scholar
• Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002). The protein kinase complement of the human genome. Science, 298(5600), 1912–1934. https://doi.org/10.1126/science.1075762
   PubMed Web of Science ®Google Scholar
• Mundt, K. E., Golsteyn, R. M., Lane, H. A., & Nigg, E. A. (1997). On the regulation and function of human polo-like kinase 1 (PLK1): Effects of overexpression on cell cycle progression. Biochemical and Biophysical Research Communications, 239(2), 377–385.https://doi.org/10.1006/bbrc.1997.7378
   PubMed Web of Science ®Google Scholar
• Olawale, F., Iwaloye, O., Elekofehinti, O. O., Kikiowo, B., Oluwarotimi, E. A., Ilesanmi, K. M., Akinropo, I. D., Akinlosotu, O. B., Adegboyega, A. E., & Ologuntere, T. E. (2021). A multi-target approach for the discovery of anti breast cancer agents from plants secondary metabolites. Letters in Drug Design & Discovery, 18, 1–15. https://doi.org/10.2174/1570180818666210521111535
   Web of Science ®Google Scholar
• Olawale, F., Olofinsan, K., Iwaloye, O., & Emmanuel, T. (2021). Phytochemicals from Nigerian medicinal plants modulate therapeutically - Relevant diabetes targets: Insight from computational direction. Advances in Traditional Medicine, 21, 1–15. https://doi.org/10.1007/s13596-021-00598-z
   Google Scholar
• Phase. (2017). Schrödinger, LLC, New York, NY.
   Google Scholar
• Pietilä, M., Vijay, G. V., Soundararajan, R., Yu, X., Symmans, W. F., Sphyris, N., & Mani, S. A. (2016). FOXC2 regulates the G2/M transition of stem cell-rich breast cancer cells and sensitizes them to PLK1 inhibition. Scientific Reports, 6(1), 23070–23012. https://doi.org/10.1038/srep23070
   PubMedGoogle Scholar
• Pines, J. (1994). Protein kinases and cell cycle control. Seminars in Cell Biology, 5(6), 399–408. https://doi.org/10.1006/scel.1994.1047
   PubMedGoogle Scholar
• Raj, D. S., Kottaisamy, C. P. D., Hopper, W., & Sankaran, U. (2021). Identification of immucillin analogue natural compounds to inhibit Helicobacter pylori MTAN through high throughput virtual screening and molecular dynamics simulation. In Silico Pharmacology, 9(1), 22. https://doi.org/10.1007/s40203-021-00081-2
   PubMedGoogle Scholar
• Roy, K., Das, R. N., Ambure, P., & Aher, R. B. (2016). Be aware of error measures. Further studies on validation of predictive QSAR models. Chemometrics and Intelligent Laboratory Systems, 152, 18–33. https://doi.org/10.1016/j.chemolab.2016.01.008
   Web of Science ®Google Scholar
• Salam, N. K., Nuti, R., & Sherman, W. (2009). Novel method for generating structure-based pharmacophores using energetic analysis. Journal of Chemical Information and Modeling, 49(10), 2356–2368. https://doi.org/10.1021/ci900212v
   PubMed Web of Science ®Google Scholar
• Santamaria, A., Neef, R., Eberspächer, U., Eis, K., Husemann, M., Mumberg, D., Prechtl, S., Schulze, V., Siemeister, G., Wortmann, L., Barr, F. A., & Nigg, E. A. (2007). Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis. Molecular Biology of the Cell, 18(10), 4024–4036. https://doi.org/10.1091/mbc.e07-05-0517
   PubMed Web of Science ®Google Scholar
• Schöffski, P., Awada, A., Dumez, H., Gil, T., Bartholomeus, S., Wolter, P., Taton, M., Fritsch, H., Glomb, P., & Munzert, G. (2012). A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. European Journal of Cancer (Oxford, England: 1990), 48(2), 179–186. https://doi.org/10.1016/j.ejca.2011.11.001
   PubMed Web of Science ®Google Scholar
• Schrodinger LLC. (2012a). Schrodinger suite 2012 protein preparation wizard; Epik verstion 2.3. Impact version 5.8, Prime vesion 3.1. Schrodinger.
   Google Scholar
• Schrödinger LLC. (2012b). QikProp, version 3.5. Schrondinger, New York, NY.
   Google Scholar
• Shelley, J. C., Cholleti, A., Frye, L. L., Greenwood, J. R., Timlin, M. R., & Uchimaya, M. (2007). Epik: A software program for pK a prediction and protonation state generation for drug-like molecules. Journal of Computer-Aided Molecular Design, 21(12), 681–691. https://doi.org/10.1007/s10822-007-9133-z
   PubMed Web of Science ®Google Scholar
• Sherman, W., Beard, H. S., & Farid, R. (2006). Use of an induced fit receptor structure in virtual screening. Chemical Biology & Drug Design, 67(1), 83–84. https://doi.org/10.1111/j.1747-0285.2005.00327.x
   PubMed Web of Science ®Google Scholar
• Singh, R., Peng, S., Viswanath, P., Sambandam, V., Shen, L., Rao, X., Fang, B., Wang, J., & Johnson, F. M. (2019). Non‐canonical cM et regulation by vimentin mediates Plk1 inhibitor–induced apoptosis. EMBO Molecular Medicine, 11(5), e9960. https://doi.org/10.15252/emmm.201809960
   PubMed Web of Science ®Google Scholar
• Smith, M. R., Wilson, M. L., Hamanaka, R., Chase, D., Kung, H., Longo, D. L., & Ferris, D. K. (1997). Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochemical and Biophysical Research Communications, 234(2), 397–405. https://doi.org/10.1006/bbrc.1997.6633
   PubMed Web of Science ®Google Scholar
• Smits, V. A. J., Klompmaker, R., Arnaud, L., Rijksen, G., Nigg, E. A., & Medema, R. H. (2000). Polo-like kinase-1 is a target of the DNA damage checkpoint. Nature Cell Biology, 2(9), 672–676. https://doi.org/10.1038/35023629
   PubMed Web of Science ®Google Scholar
• Steegmaier, M., Hoffmann, M., Baum, A., Lénárt, P., Petronczki, M., Krssák, M., Gürtler, U., Garin-Chesa, P., Lieb, S., Quant, J., Grauert, M., Adolf, G. R., Kraut, N., Peters, J.-M., & Rettig, W. J. (2007). BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Current Biology: CB, 17(4), 316–322. https://doi.org/10.1016/j.cub.2006.12.037
   PubMed Web of Science ®Google Scholar
• Strebhardt, K., & Ullrich, A. (2006). Targeting polo-like kinase 1 for cancer therapy. Nature Reviews. Cancer, 6(4), 321–330. https://doi.org/10.1038/nrc1841
   PubMed Web of Science ®Google Scholar
• Sychev, D. A., Ashraf, G. M., Svistunov, A. A., Maksimov, M. L., Tarasov, V. V., Chubarev, V. N., Otdelenov, V. A., Denisenko, N. P., Barreto, G. E., & Aliev, G. (2018). The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo. Drug Design, Development and Therapy, 12, 1147–1156. https://doi.org/10.2147/DDDT.S149069
   PubMed Web of Science ®Google Scholar
• Trott, O., & Olson, A. J. (2010). AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2), 455–461.
   PubMed Web of Science ®Google Scholar
• Truchon, J. F., & Bayly, C. I. (2007). Evaluating virtual screening methods: Good and bad metrics for the “early recognition” problem. Journal of Chemical Information and Modeling, 47(2), 488–508. https://doi.org/10.1021/ci600426e
   PubMed Web of Science ®Google Scholar
• Van den Bossche, J., Lardon, F., Deschoolmeester, V., De Pauw, I., Vermorken, J. B., Specenier, P., Pauwels, P., Peeters, M., & Wouters, A. (2016). Spotlight on volasertib: Preclinical and clinical evaluation of a promising Plk1 inhibitor. Medicinal Research Reviews, 36(4), 749–786.https://doi.org/10.1002/med.21392
   PubMed Web of Science ®Google Scholar
• Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002). Molecular properties that influence the oral bioavailability of drug candidates. Journal of Medicinal Chemistry, 45(12), 2615–2623. https://doi.org/10.1021/jm020017n
   PubMed Web of Science ®Google Scholar
• Walker, D. K. (2004). The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development. British Journal of Clinical Pharmacology, 58(6), 601–608. https://doi.org/10.1111/j.1365-2125.2004.02194.x
   PubMed Web of Science ®Google Scholar
• Wang, Z.-X., Xue, D., Liu, Z.-L., Lu, B.-B., Bian, H.-B., Pan, X., & Yin, Y.-M. (2012). Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer. The International Journal of Biochemistry & Cell Biology, 44(1), 200–210. https://doi.org/10.1016/j.biocel.2011.10.017
   PubMed Web of Science ®Google Scholar
• Watanabe, N., Sekine, T., Takagi, M., Iwasaki, J., Imamoto, N., Kawasaki, H., & Osada, H. (2009). Deficiency in chromosome congression by the inhibition of Plk1 polo box domain-dependent recognition. Journal of Biological Chemistry, 284(4), 2344–2353. https://doi.org/10.1074/jbc.M805308200
   PubMed Web of Science ®Google Scholar
• Webb, B., & Sali, A. (2016). Comparative Protein Structure Modeling Using MODELLER. Current Protocols in Bioinformatics, 54, 5.6.1–5.6.37. https://doi.org/10.1002/cpbi.3 27322406
   PubMedGoogle Scholar
• Weichert, W., Kristiansen, G., Schmidt, M., Gekeler, V., Noske, A., Niesporek, S., Dietel, M., & Denkert, C. (2005). Polo-like kinase 1 expression is a prognostic factor in human colon cancer. World Journal of Gastroenterology, 11(36), 5644. 5644. https://doi.org/10.3748/wjg.v11.i36.5644
   PubMed Web of Science ®Google Scholar
• Weichert, W., Schmidt, M., Gekeler, V., Denkert, C., Stephan, C., Jung, K., Loening, S., Dietel, M., & Kristiansen, G. (2004). Polo‐like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. The Prostate, 60(3), 240–245. https://doi.org/10.1002/pros.20050
   PubMed Web of Science ®Google Scholar
• Yang, H., Lou, C., Sun, L., Li, J., Cai, Y., Wang, Z., Li, W., Liu, G., & Tang, Y. (2019). admetSAR 2.0: Web-service for prediction and optimization of chemical ADMET properties. Bioinformatics (Oxford, England), 35(6), 1067–1069.
   PubMed Web of Science ®Google Scholar
• Yim, H. (2013). Current clinical trials with polo-like kinase 1 inhibitors in solid tumors. Anti-Cancer Drugs, 24(10), 999–1006. https://doi.org/10.1097/CAD.0000000000000007
   PubMed Web of Science ®Google Scholar
• Yuan, J., Eckerdt, F., Bereiter-Hahn, J., Kurunci-Csacsko, E., Kaufmann, M., & Strebhardt, K. (2002). Cooperative phosphorylation including the activity of polo-like kinase 1 regulates the subcellular localization of cyclin B1. Oncogene, 21(54), 8282–8292. https://doi.org/10.1038/sj.onc.1206011
   PubMed Web of Science ®Google Scholar
• Zeng, X., Zhang, P., He, W., Qin, C., Chen, S., Tao, L., Wang, Y., Tan, Y., Gao, D., Wang, B., Chen, Z., Chen, W., Jiang, Y. Y., & Chen, Y. Z. (2018). NPASS: Natural product activity and species source database for natural product research, discovery and tool development. Nucleic Acids Research, 46(D1), D1217–D1222. https://doi.org/10.1093/nar/gkx1026
   PubMed Web of Science ®Google Scholar